Arbor Biotechnologies

Arbor Biotechnologies™ - Home

Cambridge, United States · Founded 2016 · $304.5M raised

Employees
51–200
Founded
2016
Business Model
B2B
Website
arbor.bio
Total Funding
$304.5M
Last Round
$73.9M Series CMar 2025
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 5 investors for this company. The full record is or through the API.

About

Arbor Biotechnologies is a next-generation gene editing company based in Cambridge, MA, advancing a pipeline of novel genomic medicines for patients with genetic diseases. The company discovers and develops programmable DNA editors — building on CRISPR with advanced proprietary tools — to enable curative outcomes across liver, CNS, and other disease areas. Arbor partners with global pharmaceutical leaders to bring its editing platform to clinical-stage programs.

Summary

Arbor Biotechnologies is a Biotech company based in Cambridge, United States, founded in 2016. It has raised $304.5M in total across 3 rounds, most recently a $73.9M Series C round in Mar 2025. Investors include ARCH Venture Partners, TCGX and ArrowMark Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CMar 2025
$73.9M

Sign up to see all 3 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Arbor Biotechnologies on Indexed.vc
<a href="https://indexed.vc/companies/arbor-biotechnologies"><img src="https://indexed.vc/api/badge/company/arbor-biotechnologies" alt="Arbor Biotechnologies on Indexed.vc" width="260" height="76" /></a>